Acute Myeloid Leukemia Relapse after Bromodomain Inhibitor Treatment or Chemotherapy is Characterized by Myc-Ras Transcriptional Remodeling
Huang, B. J.; D'Souza, J.; Batingana, A. R.; Harris, M. D.; Wang, X.; Hwang, E.; Wandler, A. M.; Burgess, M. R.; Li, Q.; Meshinchi, S.; Bollag, G.; Shannon, K.
Show abstract
Adult and pediatric acute myeloid leukemias (AMLs) harbor distinct mutational profiles, including a higher incidence of RAS and other signaling mutations in young patients. Here we show that the BET inhibitor PLX51107 potently suppresses the growth of NRAS-mutant AML cell lines, and that these activities are enhanced by co-treatment with the MEK inhibitor PD0325901. Controlled preclinical trials in primary mouse Nras-mutant AMLs revealed single agent efficacy of PLX51107 that was enhanced by PD0325901. Leukemias that relapsed during treatment developed intrinsic drug resistance characterized by transition to a more primitive state, up-regulation of Myc target genes, and down-regulation of Ras-associated transcriptional programs. AMLs that relapsed after frontline chemotherapy showed similar transcriptional remodeling. These studies demonstrate transcriptional plasticity in primary AMLs that relapse following in vivo treatment with either targeted agents or chemotherapy, and support evaluating BET inhibition in leukemias with monocytic differentiation and RAS mutations.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML 98%
- Resistance to decitabine and 5-azacytidine emerges from adaptive responses of the pyrimidine metabolism network 98%
- Identification of leukemia stem cell subsets with distinct transcriptional, epigenetic and functional properties 97%
Similar papers in this journal
- Leukemia cell of origin influences apoptotic priming and sensitivity to LSD1 inhibition 99%
- Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia 97%
- A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy 97%
Similar papers in this journal
- Leukemia escapes immunity by imposing a Type-1 regulatory program on neoantigen-specific CD4+ T cells. 97%
- A JAK/STAT-Mediated Inflammatory Signaling Cascade Drives Oncogenesis In AF10-Rearranged AML 97%
- BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor 97%
Similar papers in this journal
Similar papers in this journal
- Acute myeloid leukemia stratifies as two clinically relevant sphingolipidomic subtypes 98%
- Modeling IKZF1 lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities 97%
- Hematopoietic fitness of JAK2 V617F Myeloproliferative Neoplasms is linked to clinical outcome 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.